5-Amino-1MQ is a small-molecule NNMT inhibitor supplied as a lyophilized research vial. NNMT is the enzyme that consumes NAD+, so inhibiting it is studied as a route to NAD+ preservation alongside SIRT1 and AMPK signaling in fat metabolism. Every finding so far comes from cell and animal work.
- Inhibits nicotinamide N-methyltransferase (NNMT), the enzyme that consumes NAD+, which is why it is studied alongside NAD+ itself.PubMed: 5-Amino-1MQ
- In preclinical work, that NNMT block raises SIRT1 and AMPK activity, the two switches tied to fat metabolism and cellular energy.Preclinical (cell and animal)
- Reported half-life is 3.8 to 6.9 hours.researchdosing
- It is a small molecule rather than a fragile peptide, so it holds structural stability well past the usual peptide window.Peptide Guide handling notes
- Honest context: approved weight-loss drugs (semaglutide, tirzepatide, orforglipron) are far better proven for the same endpoint, and the NAD+ pathway effects here remain theoretical.Peptide Guide safety review